Sign In
Buy HCM
$9.99
-0.290 (-2.82%)
At Close: Jun 22, 2026
HUTCHMED (China) Limited (HCM) Q4 2024 Earnings Call Transcript
12:17pm, Wednesday, 19'th Mar 2025
HUTCHMED (China) Limited (NASDAQ:HCM ) Q4 2024 Earnings Conference Call March 19, 2025 8:00 AM ET Company Participants David Ng - Head:IR Wei-Guo Su - CEO & Chief Scientific Officer Johnny Cheng - CFO
Hutchmed's Oncology Revenue Hits $271.5 Million, Rising 65% On Fruzaqla Strength
12:09pm, Wednesday, 19'th Mar 2025
On Wednesday, Hutchmed (China) Limited (NASDAQ: HCM) reported 2024 earnings of 22 cents per ADS or 4 cents per share, down 59 cents or 12 cents a year ago. Sales fell 25% year over year to $630.20
HUTCHMED Reports 2024 Full Year Results and Provides Business Updates
07:00am, Wednesday, 19'th Mar 2025
65% oncology products revenue growth drove profitable operation and supported new ATTC platform 65% oncology products revenue growth drove profitable operation and supported new ATTC platform
SAN FRANCISCO and SUZHOU, China , March 18, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercia
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., March 19, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) and Innovent Biologics, Inc. (“Innovent”
Gallagher Certified as Smartchoice® Preferred Provider by Brandon Hall Group
01:41pm, Monday, 10'th Mar 2025
Brandon Hall Group, the leader in Empowering, Recognizing and Certifying Excellence in HCM recently announced that Gallagher is certified as a Smartchoice® Preferred Solution Provider. Confirming tha
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., March 06, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that it has completed enroll
HUTCHMED Announces Appointment of Independent Non-executive Director and Member of Board Committee
05:00am, Wednesday, 05'th Mar 2025
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., March 05, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM:HCM, HKEX:13) today announces that Mr
HUTCHMED (HCM) Upgraded to Buy: Here's Why
01:00pm, Thursday, 20'th Feb 2025
HUTCHMED (HCM) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Wall Street Analysts Believe HUTCHMED (HCM) Could Rally 72.83%: Here's is How to Trade
10:55am, Thursday, 20'th Feb 2025
The average of price targets set by Wall Street analysts indicates a potential upside of 72.8% in HUTCHMED (HCM). While the effectiveness of this highly sought-after metric is questionable, the positi
HUTCHMED to Announce 2024 Final Results
03:30am, Wednesday, 19'th Feb 2025
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Feb. 19, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; SEHK:13) will be announcing its final results for the year
All-in-one solution fully integrates with PDI Enterprise to simplify workforce management and optimize productivity ATLANTA , Jan. 22, 2025 /PRNewswire/ -- Convenience retail and wholesale petroleum o
— Indication expands to include treatment-naïve patients — — The 2021 conditional approval in previously treated patients converted to full approval — HONG KONG and SHANGHAI and FLORHAM PARK
$HAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Paycor HCM, Inc. - PYCR
07:00pm, Tuesday, 07'th Jan 2025
NEW YORK , Jan. 7, 2025 /PRNewswire/ -- Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm by ISS Securi
Jay Whitehead Joins Asure as Senior Vice President of AsurePay(TM) and Marketplace
02:46pm, Tuesday, 07'th Jan 2025
Seasoned executive, entrepreneur, and HCM thought leader to drive innovation and foster strategy partnerships at fast-growing payroll provider Seasoned executive, entrepreneur, and HCM thought leader
